Review of T cell proliferation regulatory factors in treatment and prognostic prediction for solid tumors

• Published in: Heliyon Vol. 9; no. 11; p. e21329
• Main Authors: Li, Jiayu, Ma, Shuhan, Pei, Hongdi, Jiang, Jici, Zou, Quan, Lv, Zhibin
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01-11-2023; Elsevier
• Subjects: Cancer prognosis prediction; CAR-T; Immunocyte therapy; Review; Solid tumor; T cell proliferation and activation; T cell proliferation regulators; Solid tumor; Immunocyte therapy; T cell proliferation regulators; Cancer prognosis prediction; CAR-T; T cell proliferation and activation
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2023.e21329

T cell proliferation regulators (Tcprs), which are positive regulators that promote T cell function, have made great contributions to the development of therapies to improve T cell function. CAR (chimeric antigen receptor) -T cell therapy, a type of adoptive cell transfer therapy that targets tumor cells and enhances immune lethality, has led to significant progress in the treatment of hematologic tumors. However, the applications of CAR-T in solid tumor treatment remain limited. Therefore, in this review, we focus on the development of Tcprs for solid tumor therapy and prognostic prediction. We summarize potential strategies for targeting different Tcprs to enhance T cell proliferation and activation and inhibition of cancer progression, thereby improving the antitumor activity and persistence of CAR-T. In summary, we propose means of enhancing CAR-T cells by expressing different Tcprs, which may lead to the development of a new generation of cell therapies.